These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 3968450)

  • 81. Frequency of reexposure to Vibrio cholerae O1 evaluated by subsequent vibriocidal titer rise after an episode of severe cholera in a highly endemic area in Bangladesh.
    Weil AA; Chowdhury F; Khan AI; Leung DT; Uddin T; Begum YA; Saha NC; Charles RC; Larocque RC; Harris JB; Ryan ET; Qadri F; Calderwood SB
    Am J Trop Med Hyg; 2012 Nov; 87(5):921-6. PubMed ID: 22964723
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Circulating mucosal associated invariant T cells are activated in Vibrio cholerae O1 infection and associated with lipopolysaccharide antibody responses.
    Leung DT; Bhuiyan TR; Nishat NS; Hoq MR; Aktar A; Rahman MA; Uddin T; Khan AI; Chowdhury F; Charles RC; Harris JB; Calderwood SB; Qadri F; Ryan ET
    PLoS Negl Trop Dis; 2014 Aug; 8(8):e3076. PubMed ID: 25144724
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [The use of immunoenzyme analysis and the vibriocidal antibody reaction in the serological examination of persons who have had cholera and of those in contact with them].
    Mareev VI; Moskvitina EA; Gritsenko AN; Ivanova LV; Efanova EA; Nepomniashchaia NB; Dranov IIu; Boldyr' LA; Griseva LN
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Feb; (2):34-6. PubMed ID: 1867031
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Natural cholera infection-derived immunity in an endemic setting.
    Ali M; Emch M; Park JK; Yunus M; Clemens J
    J Infect Dis; 2011 Sep; 204(6):912-8. PubMed ID: 21849288
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Evaluation of anticoagulants for serologic assays of cholera vaccination.
    Yang JS; Kang SS; Yun CH; Han SH
    Clin Vaccine Immunol; 2014 Jun; 21(6):854-8. PubMed ID: 24717970
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The spectrum of cholera in rural Bangladesh. II. Comparison of El Tor Ogawa and classical Inaba infection.
    Woodward WE; Mosley WH
    Am J Epidemiol; 1972 Nov; 96(5):342-51. PubMed ID: 4564735
    [No Abstract]   [Full Text] [Related]  

  • 87. IgG and IgA subclass distribution of antitoxin antibody responses after oral cholera vaccination or cholera disease.
    Jertborn M; Svennerholm AM; Holmgren J
    Int Arch Allergy Appl Immunol; 1988; 85(3):358-63. PubMed ID: 3350611
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cholera in pregnancy: Clinical and immunological aspects.
    Khan AI; Chowdhury F; Leung DT; Larocque RC; Harris JB; Ryan ET; Calderwood SB; Qadri F
    Int J Infect Dis; 2015 Oct; 39():20-4. PubMed ID: 26283553
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Weak serum and intestinal antibody responses to Vibrio cholerae soluble hemagglutinin in cholera patients.
    Svennerholm AM; Levine MM; Holmgren J
    Infect Immun; 1984 Sep; 45(3):792-4. PubMed ID: 6469362
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Seroepidemiology of cholera in Gulf coastal Texas.
    Hunt MD; Woodward WE; Keswick BH; Dupont HL
    Appl Environ Microbiol; 1988 Jul; 54(7):1673-7. PubMed ID: 3415232
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Protection afforded by previous Vibrio cholerae infection against subsequent disease and infection: A review.
    Leung T; Matrajt L
    PLoS Negl Trop Dis; 2021 May; 15(5):e0009383. PubMed ID: 34014927
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Enzyme-linked immunoassays for antibodies against Vibrio cholerae.
    Cooper GN; McNab CE; Jackson GD; Walker P
    Aust J Exp Biol Med Sci; 1983 Dec; 61 ( Pt 6)():713-25. PubMed ID: 6426450
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine.
    Cash RA; Music SI; Libonati JP; Craig JP; Pierce NF; Hornick RB
    J Infect Dis; 1974 Oct; 130(4):325-33. PubMed ID: 4443613
    [No Abstract]   [Full Text] [Related]  

  • 94. Evaluation of the biological properties of different classes of human antibodies in relation to cholera.
    Majumdar AS; Ghose AC
    Infect Immun; 1981 Apr; 32(1):9-14. PubMed ID: 7216497
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Suppressive effect of zinc on antibody response to cholera toxin in children given the killed, B subunit-whole cell, oral cholera vaccine.
    Qadri F; Ahmed T; Wahed MA; Ahmed F; Bhuiyan NA; Rahman AS; Clemens JD; Black RE; Albert MJ
    Vaccine; 2004 Jan; 22(3-4):416-21. PubMed ID: 14670323
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The ABCs (Antibody, B cells, and Carbohydrate epitopes) of cholera immunity: considerations for an improved vaccine.
    Provenzano D; Kovác P; Wade WF
    Microbiol Immunol; 2006; 50(12):899-927. PubMed ID: 17179659
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Protection against experimental cholera by oral or parenteral immunization.
    Peterson JW
    Infect Immun; 1979 Nov; 26(2):594-8. PubMed ID: 546789
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cholera toxin neutralization: a comparison of purified serum IgG and biliary secretory IgA antibodies.
    Pierre P; Langendries A; Vaerman JP
    Immunol Lett; 1988 May; 18(1):51-5. PubMed ID: 3378829
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Duration of serum antitoxin response following Vibrio cholerae infection in North Americans: relevance for seroepidemiology.
    Levine MM; Young CR; Hughes TP; O'Donnell S; Black RE; Clements ML; Robins-Browne R; Lim YL
    Am J Epidemiol; 1981 Sep; 114(3):348-54. PubMed ID: 7304570
    [No Abstract]   [Full Text] [Related]  

  • 100. Intestinal immunization with soluble bacterial antigens: the example of cholera toxoid.
    Pierce NF
    Ciba Found Symp; 1976; (42):129-47. PubMed ID: 1086763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.